Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Amortization of Deferred Charges (2021 - 2024)

Bioadaptives' Amortization of Deferred Charges history spans 4 years, with the latest figure at $8387.0 for Q2 2024.

  • For Q2 2024, Amortization of Deferred Charges fell 80.1% year-over-year to $8387.0; the TTM value through Dec 2024 reached $52592.0, down 56.01%, while the annual FY2024 figure was $52592.0, 56.01% down from the prior year.
  • Amortization of Deferred Charges for Q2 2024 was $8387.0 at Bioadaptives, down from $44205.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $118450.0 in Q4 2021 and bottomed at $2680.0 in Q2 2021.
  • The 4-year median for Amortization of Deferred Charges is $43178.5 (2023), against an average of $44876.0.
  • The largest annual shift saw Amortization of Deferred Charges skyrocketed 2217.35% in 2022 before it plummeted 87.84% in 2023.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $118450.0 in 2021, then plummeted by 34.18% to $77965.0 in 2022, then tumbled by 65.07% to $27237.0 in 2023, then plummeted by 69.21% to $8387.0 in 2024.
  • Per Business Quant, the three most recent readings for BDPT's Amortization of Deferred Charges are $8387.0 (Q2 2024), $44205.0 (Q1 2024), and $27237.0 (Q4 2023).